OPEN APP
Home >Companies >Company Results >Aurobindo Pharma Q3 result: Net profit zooms over 4-fold to 2,946.32 cr
Aurobindo Pharma has notified ScieGen Pharmaceuticals of the recall and is arranging for the return of all available Irbesartan drug. Photo: Mint
Aurobindo Pharma has notified ScieGen Pharmaceuticals of the recall and is arranging for the return of all available Irbesartan drug. Photo: Mint

Aurobindo Pharma Q3 result: Net profit zooms over 4-fold to 2,946.32 cr

  • Aurobindo Pharma today reported an over 4-fold jump in its consolidated net profit to 2,946.32 cr for the quarter ended Dec 31, 2020 as against 705.31 cr for the corresponding period of the previous fiscal
  • Aurobindo Pharma's board has approved a third interim dividend of 1.5 per equity share of 1/- for the financial year 2020-21

NEW DELHI : Drug firm Aurobindo Pharma on Wednesday reported an over four-fold jump in its consolidated net profit to 2,946.32 crore for the quarter ended December 31, 2020 mainly on account of one time exceptional gains.

The company had posted a net profit of 705.31 crore for the corresponding period of the previous fiscal, Aurobindo Pharma said in a BSE filing.

The consolidated revenue from operations of the company stood at 6,364.91 crore. It was 5,895 crore for the same period a year ago, it added.

The profit before tax includes exceptional items of 2,813.89 crore for the quarter ended in December consists of disposal of business assets of a wholly-owned step-down subsidiary, Natrol LLC, on account of remeasurement of equity interest in Eugia Pharma Specialties Ltd and impairment charges taken considering the difficult economic conditions and the continued impact of COVID 19 in certain markets towards product-related intangibles and goodwill, the filing said.

"We maintained growth momentum in our revenue and profitability despite COVID challenges. We are witnessing steady progress in our specialty pipeline and continue to focus on growing our business, improving efficiencies and productivity", Aurobindo Pharma Managing Director N Govindarajan said.

The board has approved a third interim dividend of 1.5 per equity share of Re 1/- for the financial year 2020-21, the filing said.

Shares of Aurobindo Pharma closed at 967.85 per scrip on BSE, up 0.88% from its previous close.

Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Click here to read the Mint ePaperMint is now on Telegram. Join Mint channel in your Telegram and stay updated with the latest business news.

Close
×
Edit Profile
My ReadsRedeem a Gift CardLogout